RESUMO
Objetivo En el contexto de reformas de los sistemas de salud es impostergable el desarrollo de proyectos de investigación evaluativa para identificar buenas prácticas. En este sentido el objetivo de este estudio fue identificar indicadores de gobernanza y protección social en salud. Métodos Investigación evaluativa con universo de estudio referido al sistema de salud para no asegurados en seis Estados de México. Para los datos primarios se realizaron entrevistas a profundidad con informantes clave de los Estados participantes; para los datos secundarios se utilizaron estadísticas oficiales y los resultados del proyecto macro sobre reformas, políticas de salud y gobernanza en México. El procesamiento y análisis de datos se realizó con dos paquetes de software: Atlas Ti y Policy Maker. Resultados Una lista de fortalezas y debilidades se presenta como evidencia de la gobernanza del sistema de salud. La rendición de cuentas en el nivel federal, aunque no está ausente, se mantiene con un carácter prescriptivo, en los Estados y municipios aún está ausente un sistema de rendición de cuentas y de transparencia en la asignación de recursos y en cuanto a las estrategias de democratización de la salud. Conclusiones En todos los Estados hay bajos niveles de gobernanza y dificultad en la conducción efectiva de programas y estrategias de reforma con falta de precisión en las reglas y los roles con que operan los diferentes actores del sistema de salud.
Objective Evaluative research projects for identifying good practice have been postponed regarding health system reform. This study was thus aimed at identifying health governance and social protection indicators. Methods This study involved evaluative research regarding the health system for the uninsured part of the population in six Mexican states. The primary data was obtained from in-depth interviews with key players from the participating states; official statistics and the results of a macro-project concerned with Mexican health and governance reform and policy was used for secondary. Atlas Ti and Policy Maker software were used for processing and analysing the data. Results A list of strengths and weaknesses was presented as evidence of health system governance. Accountability at federal level (even though not lacking) was of a prescriptive nature and a system of accountability and transparency regarding the assignment of resources and strategies for the democratisation of health in the states and municipalities was still lacking. Conclusions All six states had low levels of governance and experienced difficulty in conducting effective reform programmes and strategies involving a lack of precision regarding the rules and roles adopted by different health system actors.
Assuntos
Adolescente , Humanos , Masculino , Hiperamonemia/tratamento farmacológico , Serviço de Farmácia Hospitalar , Fenilacetatos/uso terapêutico , Química Farmacêutica , Hiperamonemia/sangue , Serviço de Farmácia Hospitalar/métodos , Fenilacetatos/síntese química , PósRESUMO
IDPH-8261, methyl alpha-methyl-4-(3-thienyl)benzeneacetate, exhibited marked anti-inflammatory activity in acute, subacute and chronic models of inflammation. In rats, IDPH-8261 exhibited a dose related inhibition of carrageenin-induced rat paw edema and the inhibition was greater than ibuprofen, phenylbutazone, but was three times less than indomethacin. It exhibited anti-inflammatory activity in normal and adrenalectomized rats. It also exhibited the activity against various phlogistic agents. IDPH-8261 exhibited AI activity in subacute granuloma tests. In adjuvant-induced established polyarthritis. IDPH-8261 exhibited anti-arthritic effect at a very low dose (ED50 = 4 mg/kg, p.o.). Ulcerogenic liability was the lowest (UD50 = 180 mg/kg, p.o.), when compared to reference standard drugs. Low toxicity and high efficacy may make this compound a potentially useful therapeutic agent.